Diagnosis of Atopic Dermatitis: Mimics, Overlaps, and Complications
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Contact Vitiligo Following Allergic Contact Dermatitis *Ricardo Ruiz-Villaverde, Francisco J Navarro-Triviño
SUBMITTED 19 JAN 21 REVISION REQ. 17 MAR 21; REVISION 5 APR 21 ACCEPTED 21 APR 21 ONLINE-FIRST: MAY 2021 DOI: https://doi.org/10.18295/squmj.5.2021.078 Contact Vitiligo Following Allergic Contact Dermatitis *Ricardo Ruiz-Villaverde, Francisco J Navarro-Triviño Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain *Corresponding Author’s e-mail: [email protected] Introduction A 45-year-old man, construction worker, with no personal history of psoriasis, atopic dermatitis, and vitiligo, was referred to our Contact Eczema Department with a chronic hand eczema and skin depigmentation over a period of 12 months. Skin depigmentation appeared few months later regarding the primary eczema. The patient reported the use of rubber gloves for many years. He had noticed itching and mild erythema over both hands. Currently, he wears nitrile gloves at work. Physical examination showed symmetric erythematous-squamous, hyperkeratotic and fissured plaques on both hands (Fig. 1A), and ventral aspect of wrists (Fig. 1B). Skin depigmentation areas showed irregular edges (Fig. 1C). Wood´s lamp examination accentuated the depigmentation areas overlap the eczema (Fig. 2A-B), without vitiligo pattern. No other anatomical sites were involved. Blood test showed no significant alterations, including data from autoimmune thyroiditis, celiac disease, and pernicious anaemia. Patch tests were performed with the European Comprehensive Baseline Series (Chemotechnique Diagnostics, Vellinge, Sweden), rubber additives series (Chemotechnique Diagnostics), and hydroquinone monobenzylether 1% pet (Shoe series, Chemotechnique Diagnosis). The results were interpreted according to the criteria of the International Contact Dermatitis Research Group. Patch tests were read on day (D) 2 and D4. -
Autoimmune Associations of Alopecia Areata in Pediatric Population - a Study in Tertiary Care Centre
IP Indian Journal of Clinical and Experimental Dermatology 2020;6(1):41–44 Content available at: iponlinejournal.com IP Indian Journal of Clinical and Experimental Dermatology Journal homepage: www.innovativepublication.com Original Research Article Autoimmune associations of alopecia areata in pediatric population - A study in tertiary care centre Sagar Nawani1, Teki Satyasri1,*, G. Narasimharao Netha1, G Rammohan1, Bhumesh Kumar1 1Dept. of Dermatology, Venereology & Leprosy, Gandhi Medical College, Secunderabad, Telangana, India ARTICLEINFO ABSTRACT Article history: Alopecia areata (AA) is second most common disease leading to non scarring alopecia . It occurs in Received 21-01-2020 many patterns and can occur on any hair bearing site of the body. Many factors like family history, Accepted 24-02-2020 autoimmune conditions and environment play a major role in its etio-pathogenesis. Histopathology shows Available online 29-04-2020 bulbar lymphocytes surrounding either terminal hair or vellus hair resembling ”swarm of bees” appearance depending on chronicity of alopecia areata. Alopecia areata in children is frequently seen. Pediatric AA has been associated with atopy, thyroid abnormalities and a positive family history. We have done a study to Keywords: find out if there is any association between alopecia areata and other auto immune diseases in children. This Alopecia areata study is an observational study conducted in 100 children with AA to determine any associated autoimmune Auto immunity conditions in them. SALT score helps to assess severity of alopecia areata. Severity of alopecia areata was Pediatric population assessed by SALT score-1. S1- less than 25% of hairloss, 2. S2- 25-49% of hairloss, 3. 3.S3- 50-74% of hairloss. -
The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis Rana Herro1, Ricardo Da S
ORIGINAL ARTICLE The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis Rana Herro1, Ricardo Da S. Antunes1, Amelia R. Aguilera1, Koji Tamada2 and Michael Croft1 Several inflammatory diseases including scleroderma and atopic dermatitis display dermal thickening, epidermal hypertrophy, or excessive accumulation of collagen. Factors that might promote these features are of interest for clinical therapy. We previously reported that LIGHT, a TNF superfamily molecule, mediated collagen deposition in the lungs in response to allergen. We therefore tested whether LIGHT might similarly promote collagen accumulation and features of skin fibrosis. Strikingly, injection of recombinant soluble LIGHT into naive mice, either subcutaneously or systemically, promoted collagen deposition in the skin and dermal and epidermal thickening. This replicated the activity of bleomycin, an antibiotic that has been previously used in models of scleroderma in mice. Moreover skin fibrosis induced by bleomycin was dependent on endogenous LIGHT activity. The action of LIGHT in vivo was mediated via both of its receptors, HVEM and LTβR, and was dependent on the innate cytokine TSLP and TGF-β. Furthermore, we found that HVEM and LTβR were expressed on human epidermal keratinocytes and that LIGHT could directly promote TSLP expression in these cells. We reveal an unappreciated activity of LIGHT on keratinocytes and suggest that LIGHT may be an important mediator of skin inflammation and fibrosis in diseases such as scleroderma -
Seborrheic Dermatitis: an Overview ROBERT A
Seborrheic Dermatitis: An Overview ROBERT A. SCHWARTZ, M.D., M.P.H., CHRISTOPHER A. JANUSZ, M.D., and CAMILA K. JANNIGER, M.D. University of Medicine and Dentistry at New Jersey-New Jersey Medical School, Newark, New Jersey Seborrheic dermatitis affects the scalp, central face, and anterior chest. In adolescents and adults, it often presents as scalp scaling (dandruff). Seborrheic dermatitis also may cause mild to marked erythema of the nasolabial fold, often with scaling. Stress can cause flare-ups. The scales are greasy, not dry, as commonly thought. An uncommon generalized form in infants may be linked to immunodeficiencies. Topical therapy primarily consists of antifungal agents and low-potency steroids. New topical calcineurin inhibitors (immunomodulators) sometimes are administered. (Am Fam Physician 2006;74:125-30. Copyright © 2006 American Academy of Family Physicians.) eborrheic dermatitis can affect patients levels, fungal infections, nutritional deficits, from infancy to old age.1-3 The con- neurogenic factors) are associated with the dition most commonly occurs in condition. The possible hormonal link may infants within the first three months explain why the condition appears in infancy, S of life and in adults at 30 to 60 years of age. In disappears spontaneously, then reappears adolescents and adults, it usually presents as more prominently after puberty. A more scalp scaling (dandruff) or as mild to marked causal link seems to exist between seborrheic erythema of the nasolabial fold during times dermatitis and the proliferation of Malassezia of stress or sleep deprivation. The latter type species (e.g., Malassezia furfur, Malassezia tends to affect men more often than women ovalis) found in normal dimorphic human and often is precipitated by emotional stress. -
EAACI/ESCD Skin Allergy Meeting 2017 (SAM 2017)
Clin Transl Allergy 2017, 7(Suppl 4):47 DOI 10.1186/s13601-017-0184-5 Clinical and Translational Allergy MEETING ABSTRACTS Open Access EAACI/ESCD Skin Allergy Meeting 2017 (SAM 2017) Zurich, Switzerland. 27 – 29 April 2017 Published: 15 December 2017 Thursday, 27 April 2017 O02 Assessment of aggregate consumer exposure to isothiazolinones O01 via cosmetics and detergents Methylisothiazolinone contact allergy: a real outbreak Elena Garcia Hidalgo, Natalie Von Goetz, Konrad Hungerbühler Luis Amaral1, Emidio Silva2, Marcio Oliveira3, Ana Paula Cunha4 ETH Zürich, Zürich, Switzerland 1Serviço de Imunoalergologia, Centro Hospitalar de São João E.P.E., Porto, Correspondence: Elena Garcia Hidalgo ‑ [email protected] Portugal; 2Serviço de Medicina do Trabalho e Saúde Ocupacional, Centro Clinical and Translational Allergy 2017, 7(Supple 4):O02 Hospitalar do Baixo Vouga E.P.E., Aveiro, Portugal; 3Serviço de Saúde Ocu‑ pacional, Centro Hospitalar de São João E.P.E., Porto, Portugal; 4Serviço de Background: Isothiazoliones can cause allergic contact dermati- Dermatologia, Centro Hospitalar de São João E.P.E., Porto, Portugal tis and are present in a variety of consumer products, such as cos- Correspondence: Luis Amaral ‑ [email protected] metics, detergents and do-it-yourself products. Skin sensitization Clinical and Translational Allergy 2017, 7(Supple 4):O01 is induced following dermal exposure to a sensitizer in an amount exceeding the sensitization threshold. The critical determinant of Background: Methylisothiazolinone (MI) is used as a preservative in exposure for evaluating skin sensitization risks is dose per unit area occupational, domestic products and, since 2005, in cosmetics. It is a of exposed skin. -
Gianotti-Crosti Syndrome
GIANOTTI-CROSTI SYNDROME http://www.aocd.org Gianotti-Crosti Syndrome (GCS) is also known as ‘papular acrodermatitis of childhood’ and ‘papulovesicular acrolated syndrome’. GCS is a viral eruption that typically begins on the buttocks and spreads to other areas of the body. The rash also affects the face and the extremities. The chest, back, belly, palms and soles are usually spared. In the United States, it is most commonly caused by Epstein-Barr virus infection. Hepatitis B is a common cause in parts of the world where the vaccination is not given. Other viruses that cause the rash include hepatitis A and C, cytomegalovirus, enterovirus, coxsackievirus, rotavirus, adenovirus, human herpes virus-6, respiratory syncytial virus, parvovirus B10, rubella, HIV, and parainfluenza. It has also been associated with viral immunizations for poliovirus, hepatitis A, diphtheria, small pox, pertussis and influenza. GCS most commonly occurs in children between the ages of one to three but can occur at any time from the ages of three months to fifteen years. The condition manifests more commonly in the spring and summer and lasts for four weeks but can last up to eight weeks. The rash has been known to occur more commonly in children with atopic dermatitis. The lesions present as single, red to pink to brown colored bumps that may be fluid-filled. The size of the lesions can range from one to ten millimeters and present symmetrically. The bumps can come together and form larger lesions. Sometimes the child may present with a fever, enlarged tender lymph nodes and an enlarged spleen or liver. -
Counsyl Foresight™ Carrier Screen Disease List
COUNSYL FORESIGHT™ CARRIER SCREEN DISEASE LIST The Counsyl Foresight Carrier Screen focuses on serious, clinically-actionable, and prevalent conditions to ensure you are providing meaningful information to your patients. 11-Beta-Hydroxylase- Bardet-Biedl Syndrome, Congenital Disorder of Galactokinase Deficiency Deficient Congenital Adrenal BBS1-Related (BBS1) Glycosylation, Type Ic (ALG6) (GALK1) Hyperplasia (CYP11B1) Bardet-Biedl Syndrome, Congenital Finnish Nephrosis Galactosemia (GALT ) 21-Hydroxylase-Deficient BBS10-Related (BBS10) (NPHS1) Gamma-Sarcoglycanopathy Congenital Adrenal Bardet-Biedl Syndrome, Costeff Optic Atrophy (SGCG) Hyperplasia (CYP21A2)* BBS12-Related (BBS12) Syndrome (OPA3) Gaucher Disease (GBA)* 6-Pyruvoyl-Tetrahydropterin Bardet-Biedl Syndrome, Cystic Fibrosis GJB2-Related DFNB1 Synthase Deficiency (PTS) BBS2-Related (BBS2) (CFTR) Nonsyndromic Hearing Loss ABCC8-Related Beta-Sarcoglycanopathy and Deafness (including two Cystinosis (CTNS) Hyperinsulinism (ABCC8) (including Limb-Girdle GJB6 deletions) (GJB2) Muscular Dystrophy, Type 2E) D-Bifunctional Protein Adenosine Deaminase GLB1-Related Disorders (SGCB) Deficiency (HSD17B4) Deficiency (ADA) (GLB1) Biotinidase Deficiency (BTD) Delta-Sarcoglycanopathy Adrenoleukodystrophy: GLDC-Related Glycine (SGCD) X-Linked (ABCD1) Bloom Syndrome (BLM) Encephalopathy (GLDC) Alpha Thalassemia (HBA1/ Calpainopathy (CAPN3) Dysferlinopathy (DYSF) Glutaric Acidemia, Type 1 HBA2)* Canavan Disease Dystrophinopathies (including (GCDH) (ASPA) Alpha-Mannosidosis Duchenne/Becker Muscular -
Download WAO White Book on Allergy
WORLD ALLERGY ORGANIZATION WAWAOO WhiteWhite BookBook onon AllergyAllergy WAO White Book on Allergy World Allergy Organization (WAO) White Book on Allergy Copyright 2011 World Allergy Organization WAO White Book on Allergy Editors Prof. Ruby Pawankar, MD, PhD Prof. Giorgio Walter Canonica, MD WAO President Elect (2010-2011) WAO Past President (2010-2011) Allergy and Rhinology Allergy & Respiratory Diseases Nippon Medical School Department of Internal Medicine 1-1-5 Sendagi, Bunkyo-ku University of Genoa Tokyo 113-8603 Padiglione Maragliano, Largo Rosanna Benzi 10 JAPAN 1-16132 Genoa ITALY Prof. Stephen T. Holgate, BSc, MD, DSc, FMed Sci Prof. Richard F. Lockey, MD Member, WAO Board of Directors (2010-2011) WAO President (2010-2011) Medical Research Council Clinical Professor of Division of Allergy & Immunology Immunopharmacology Joy McCann Culverhouse Chair in Allergy & Immunology Infection, Inflammation and Immunity University of South Florida College of Medicine School of Medicine James Haley Veterans Administration Medical Center (111D) University of Southampton 13000 Bruce B. Downs Boulevard Level F, South Block Tampa, Florida 33612 Southampton General Hospital USA Tremona Road Southampton SO16 6YD United Kingdom Acknowledgement On behalf of the World Allergy Organization (WAO), the editors and authors of the WAO White Book on Allergy express their gratitude to the charity, Asthma, Allergy, Inflammation Research (AAIR) and Asian Allergy Asthma Foundation (AAAF) for their support in the production of this publication. The Editors of the White book extend their gratitude to His Excellency Dr. APJ Abdul Kalam, Former President of India and Madame Ilora Finlay Baronness of the House of Lords for their Forewords to the White Book and to the International Primary Care Respiratory Group (IPCRG) and European Federation of Allergy and Airways Diseases Patients ‘Associations (EFA) for their supporting statements. -
Scalp Eczema Factsheet the Scalp Is an Area of the Body That Can Be Affected by Several Types of Eczema
12 Scalp eczema factsheet The scalp is an area of the body that can be affected by several types of eczema. The scalp may be dry, itchy and scaly in a chronic phase and inflamed (red), weepy and painful in an acute (eczema flare) phase. Aside from eczema, there are a number of reasons why the scalp can become dry and itchy (e.g. psoriasis, fungal infection, ringworm, head lice etc.), so it is wise to get a firm diagnosis if there is uncertainty. Types of eczema • Hair clips and headgear – especially those containing that affect the scalp rubber or nickel. Seborrhoeic eczema (dermatitis) is one of the most See the NES booklet on Contact Dermatitis for more common types of eczema seen on the scalp and hairline. details. It can affect babies (cradle cap), children and adults. The Irritant contact dermatitis is a type of eczema that skin appears red and scaly and there is often dandruff as occurs when the skin’s surface is irritated by a substance well, which can vary in severity. There may also be a rash that causes the skin to become dry, red and itchy. on other parts of the face, such as around the eyebrows, For example, shampoos, mousses, hair gels, hair spray, eyelids and sides of the nose. Seborrhoeic eczema can perm solution and fragrance can all cause irritant contact become infected. See the NES factsheets on Adult dermatitis. See the NES booklet on Contact Dermatitis for Seborrhoeic Dermatitis and Infantile Seborrhoeic more details. Dermatitis and Cradle Cap for more details. -
Pompholyx Factsheet Pompholyx Eczema (Also Known As Dyshidrotic Eczema/Dermatitis) Is a Type of Eczema That Usually Affects the Hands and Feet
12 Pompholyx factsheet Pompholyx eczema (also known as dyshidrotic eczema/dermatitis) is a type of eczema that usually affects the hands and feet. In most cases, pompholyx eczema involves the development of intensely itchy, watery blisters, mostly affecting the sides of the fingers, the palms of the hands and soles of the feet. Some people have pompholyx eczema on their hands and/or feet with other types of eczema elsewhere on the body. This condition can occur at any age but is usually seen in adults under 40, and is more common in women. The skin is initially very itchy with a burning sensation of heat and prickling in the palms and/or soles. Then comes a sudden crop of small blisters (vesicles), which turn into bigger weepy blisters, which can become infected, causing redness, pain, swelling and pustules. There is often subsequent peeling as the skin dries out, and then the skin can become red and dry with painful cracks (skin fissures). Pompholyx eczema can also affect the nail folds and skin around the nails, causing swelling (paronychia). What causes it? A reaction could be the result of contact with potential irritants such as soap, detergents, solvents, acids/alkalis, The exact causes of pompholyx eczema are not known, chemicals and soil, causing irritant contact dermatitis. Or although it is thought that factors such as stress, there could be an allergic reaction to a substance that is sensitivity to metal compounds (such as nickel, cobalt or not commonly regarded as an irritant, such as rubber or chromate), heat and sweating can aggravate this nickel, causing allergic contact dermatitis. -
Child Neurology: Hereditary Spastic Paraplegia in Children S.T
RESIDENT & FELLOW SECTION Child Neurology: Section Editor Hereditary spastic paraplegia in children Mitchell S.V. Elkind, MD, MS S.T. de Bot, MD Because the medical literature on hereditary spastic clinical feature is progressive lower limb spasticity B.P.C. van de paraplegia (HSP) is dominated by descriptions of secondary to pyramidal tract dysfunction. HSP is Warrenburg, MD, adult case series, there is less emphasis on the genetic classified as pure if neurologic signs are limited to the PhD evaluation in suspected pediatric cases of HSP. The lower limbs (although urinary urgency and mild im- H.P.H. Kremer, differential diagnosis of progressive spastic paraplegia pairment of vibration perception in the distal lower MD, PhD strongly depends on the age at onset, as well as the ac- extremities may occur). In contrast, complicated M.A.A.P. Willemsen, companying clinical features, possible abnormalities on forms of HSP display additional neurologic and MRI abnormalities such as ataxia, more significant periph- MD, PhD MRI, and family history. In order to develop a rational eral neuropathy, mental retardation, or a thin corpus diagnostic strategy for pediatric HSP cases, we per- callosum. HSP may be inherited as an autosomal formed a literature search focusing on presenting signs Address correspondence and dominant, autosomal recessive, or X-linked disease. reprint requests to Dr. S.T. de and symptoms, age at onset, and genotype. We present Over 40 loci and nearly 20 genes have already been Bot, Radboud University a case of a young boy with a REEP1 (SPG31) mutation. Nijmegen Medical Centre, identified.1 Autosomal dominant transmission is ob- Department of Neurology, PO served in 70% to 80% of all cases and typically re- Box 9101, 6500 HB, Nijmegen, CASE REPORT A 4-year-old boy presented with 2 the Netherlands progressive walking difficulties from the time he sults in pure HSP. -
2U11/13U195 Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ n n 20 October 2011 (20.10.2011) 2U11/13U195 Al (51) International Patent Classification: ka Pharmaceutical Co., Ltd., 1-7-1, Dosho-machi, Chuo- C12P 19/34 (2006.01) C07H 21/04 (2006.01) ku, Osaka-shi, Osaka 541-0045 (JP). (21) International Application Number: (74) Agents: KELLOGG, Rosemary et al; Swanson & PCT/US201 1/032017 Bratschun, L.L.C., 8210 SouthPark Terrace, Littleton, Colorado 80120 (US). (22) International Filing Date: 12 April 201 1 (12.04.201 1) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, English (25) Filing Language: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 61/323,145 12 April 2010 (12.04.2010) US KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (71) Applicants (for all designated States except US): SOMA- ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, LOGIC, INC. [US/US]; 2945 Wilderness Place, Boulder, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, Colorado 80301 (US). OTSUKA PHARMACEUTI¬ SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, CAL CO., LTD.